DESIGN AND TESTING OF DUAL-TARGETED FINE-TUNED IMMUNE-RESTORING (DFIR) CAR T-CELL THERAPY TO ACHIEVE CURES OF HIGH-GRADE SEROUS OVARIAN CANCER.

Dana-Farber Cancer Institute, Inc.

Investigators